- Home
- RIGL vs NMAI Comparison
RIGL vs NMAI Comparison
Compare RIGL & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | NMAI |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 455.9M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | NMAI |
|---|---|---|
| Price | $29.36 | $13.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 313.7K | 85.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 19.48 | 0.64 |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | ★ $1.48 | $21.67 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $16.88 | $11.98 |
| 52 Week High | $52.24 | $13.96 |
Technical Indicators
Market Signals| Indicator | RIGL | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 67.41 |
| Support Level | $28.08 | $13.43 |
| Resistance Level | $30.59 | N/A |
| Average True Range (ATR) | 1.13 | 0.23 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 16.16 | 82.81 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.